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ABSTRACT

COMPARISON OF ANTHROPOMETRIC MEASUREMENTS OF ABDOMINAL
OBESITY AS PREDICTORS OF CARDIOMETABOLIC RISK FACTORS:
NHANES 2011-2014
by
Carli Kettel
June 2017

Background It has been well established that screening tools for cardiometabolic diseases
are less useful among obese populations as risk of these diseases is already high.
However, research is lacking in regard to efficient screening tools for cardiometabolic
diseases among normal weight and overweight populations.
Objective This study compared the predictive strengths of body mass index (BMI), waist
circumference (WC), waist-to-height ratio (WHtR), sagittal abdominal diameter (SAD),
and SAD-to-height ratio (SADHtR) with respect to risk of cardiometabolic disorders in
normal and overweight U.S. populations.
Design This cross-sectional study utilized data from the 2011-2014 National Health and
Nutrition Examination Survey.
Participants/setting The sample included non-pregnant adults with a normal weight or
overweight BMI status (≥ 20 years; n = 6482).
Main outcome measures Each anthropometric measure was assessed for predicting risk
of the following cardiometabolic disorders: hypertension (HTN), pre-diabetes, diabetes,
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high total cholesterol, low high-density lipoprotein cholesterol (HDL-C), high non-HDLC, and high apolipoprotein B.
Statistical analyses performed Simple and multiple logistic regression analyses
compared the odds ratio of each anthropometric measure for each cardiometabolic
disorder.
Results When analyzed in separate models, BMI, WC, WHtR, SAD, and SADHtR
identified all cardiometabolic risks. In simultaneous models with abdominal obesity
measures, BMI no longer identified cardiometabolic risks (ORs <1.0), except low HDL-C.
Among normal weight and overweight men, WHtR and SADHtR were stronger measures
of cardiometabolic risk except low HDL-C. With normal weight and overweight women,
WHtR and SADHtR were stronger measures of risk for hypertension and diabetes, while
all of the abdominal obesity measures were similar in assessment of the remaining
cardiometabolic risks.
Conclusion In normal weight and overweight adults, anthropometric measures of
abdominal obesity, especially those including a factor of height, are better predictors of
cardiometabolic risk than BMI and should be a primary screening tool in this population.
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CHAPTER I

INTRODUCTION
While obesity rates in the United States (U.S.) have started to plateau based on
body mass index (BMI) measurements, abdominal obesity rates are on the rise according
to measures of waist circumference.1,2 Abdominal obesity, as compared with other
distributions of adipose tissue, has specifically been shown to be highly associated with
chronic diseases such as diabetes, cardiovascular diseases, and other cardiometabolic
diseases.3–5
BMI has traditionally been used for the assessment of body weight but has been
shown to lack accuracy in terms of body composition. Waist circumference (WC), waistto-height ratio (WHtR), and sagittal abdominal diameter (SAD) are several measures that
are used in assessing abdominal obesity, with SAD being a relatively newer measure.
SAD is measured in the supine position using a caliper positioned in the center of the
abdomen, midway between the left and right iliac crests, measuring the height of the
abdomen, which has been shown to be associated with the amount of visceral fat in the
abdomen. Since SAD measurements only require the use of a specialized caliper, this
allows for the measurement to be easy, fast, and inexpensive compared to the more
precise yet radiation-emitting magnetic resonance imaging and dual-energy x-ray
absorptiometry.
To date, a limited number of large-scale studies have been conducted evaluating
SAD with various cardiometabolic risks in the U.S. adult population. A study in 2005 by
Smith et al. found among men that SAD was a stronger predictor of coronary heart

disease risk when divided by thigh circumference, known as the abdominal diameter
index.6 In 2013, Gletsu-Miller et al. found that SAD was stronger at predicting levels of
visceral adipose tissue, and thus the ability to predict risk of dysglycemia, than WC after
controlling for confounding variables among a small sample of severely obese women.7
Similarly, in 2014, Kahn et al. found that SAD was associated with dysglycemia among
men and women independently from WC and BMI in a nationally representative sample
of the U.S. population.8 These findings suggest that SAD may be a useful screening tool
in the U.S. population among men and women.
Since WHtR has often been shown to be a better measure of abdominal obesity
than WC alone, it is logical to expect that SAD may be more effectively used as the
SAD-to-height ratio (SADHtR).9,10 Few studies have investigated the relationship
between metabolic risks and SADHtR, with only two studies having been conducted in
the U.S. population. One of the studies focused on various abdominal measures and their
associations with sex, age, socioeconomic status, and ethnicity, rather than comparing
efficacy of abdominal obesity measures.11 The second study compared several
anthropometric measures, including SAD and SADHtR, against cardiometabolic risks in
a nationally representative sample of the U.S. population using National Health and
Nutrition Examination Survey (NHANES) 2011-2012 data. In that study, Kahn et al.
found that SADHtR and WHtR were better at predicting risk of cardiometabolic disorders
than BMI12; suggesting that SADHtR may be a better screening tool, especially compared
to BMI.
Current disease-related research focuses primarily on the whole population,
including obese individuals. However, obese populations are already at a high risk of
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developing obesity-related diseases making abdominal obesity measures relatively
unimportant. When determining a useful screening tool for obesity-related diseases, it is
important to find a tool that also works well in normal weight and overweight
populations. In some studies, an overweight status has been suggested to be protective,
especially among older adults.13,14 However, recent research suggests that an overweight
BMI status based on highest lifetime BMI is associated with increased risk of
cardiovascular and all-cause mortality.15 This implies the need for an abdominal obesity
measure among normal weight and overweight populations that may predict disease risk
before the development of the disease occurs. Therefore, the objectives of this study
include: 1) to compare the predictive strengths of BMI, WC, WHtR, SAD, and SADHtR
with respect to risk of cardiometabolic disorders in the normal and overweight U.S. adult
population; 2) to compare WC against WHtR, and SAD against SADHtR ratio to
determine whether height improves the predictive strengths; and 3) to compare WC
against SAD and WHtR and SADHtR to determine which provides the strongest
predictive strength of cardiometabolic disorders. It is hypothesized that abdominal
obesity measures will be stronger than BMI in cardiometabolic risk prediction and that
the inclusion of height with these measures will only strengthen their ability to assess
risk.
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CHAPTER II

LITERATURE REVIEW

Abdominal Obesity
Abdominal obesity is defined as excess fat in the stomach area and is recognized for
its associated risks with cardiovascular disease and insulin resistance, compared to other
areas of adiposity in the body.10,16,17 Abdominal adiposity includes subcutaneous and
visceral fat, yet visceral fat has been shown to be more associated with chronic disease
than subcutaneous fat.3–5 Subcutaneous fat may also play a role in abdominal obesity as it
consists of two layers of fat, superficial and deep subcutaneous fat. Deep subcutaneous
fat is suspected to play a bigger role in the development of chronic disease than
superficial subcutaneous fat, specifically with insulin resistance.18

Anthropometric Measurements
Body Mass Index
Body mass index (BMI) is the most commonly used screening tool in predicting
high body fatness by clinicians. This likely is due to it being an easy and inexpensive
measurement requiring only a scale and a stadiometer, both of which are available in all
hospitals and clinics. While BMI is used to predict body fatness, it does not measure the
body’s adiposity, possibly missing individuals at a higher disease risk that have a large
waist or high visceral adiposity yet normal BMI. BMI is measured by dividing an
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individual’s body weight in kilograms by their height in meters squared. The reference
ranges for BMI include:
•

Underweight: < 18.5 kg/m2

•

Normal weight: 18.5-24.9 kg/m2

•

Overweight: 35-29.9 kg/m2

•

Obese: ≥ 30 kg/m2

A recent study by Padwal et al. consisting of a cohort of over 49,000 individuals over the
age of 40 investigated associations between BMI and body fat percentage with mortality.
Adjusted Cox proportional hazards regression models revealed that a low BMI and high
body fat percentage are independently associated with increased risk of mortality.19
However, a low BMI in this case may suggest weight loss related to illness which
generally also included a loss of lean body mass. Yu et al. also observed all-cause and
cause-specific mortality related to BMI among several cohort studies, but were able to
look at a weight history for each participant rather than a single BMI measurement.15 By
using a weight history, Yu et al. were able to distinguish weight loss related to illness
versus intentional weight loss. This revealed that individuals with unintentional weight
loss were associated with an increased risk of mortality while those with intentional
weight loss had a lower risk of mortality. Within their weight history, individuals with a
maximum BMI of overweight or higher were associated with increased risk of all-cause
mortality and cause-specific mortality, especially cardiovascular disease and coronary
heart disease related deaths. Another recent cohort study by Tanamas et al. found that
individuals with a normal BMI and an obese waist circumference (≥102 cm in men, ≥88
cm in women), or an obese BMI and obese waist circumference were at increased risk of
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all-cause and cardiovascular disease mortality compared to individuals with a normal
BMI and waist circumference.20 With an inability to measure body composition, BMI
should be used in combination with other assessments of adiposity to estimate disease
risk.

Waist Circumference
Waist circumference (WC), another commonly used anthropometric measure,
predicts disease risk by measuring central adiposity. This has been shown to be more
beneficial for individuals in the normal or overweight BMI reference range, as the
predictive power of WC is less effective beyond a BMI of 35 kg/m2.21 Central adiposity
is more associated with cardiometabolic disease risk related to increased levels of visceral
fat,22 perhaps making it a more ideal screening tool compared to BMI. The reference
ranges for a high WC include:
•

Males: > 40” (101 cm)

•

Females: > 35” (88 cm)

With gender-specific reference ranges, WC can be even more specific in predicting
disease risk. In a large prospective study by Schulze et al., WC appeared to be the
strongest measure among men and women in predicting risk of diabetes compared to
BMI, waist-to-hip ratio (WHR), and waist-to-height ratio. However, once stratified by
gender, waist-to-height ratio was a stronger predictor of diabetes risk among men and
waist-to-height ratio and WC were deemed equal predictors of diabetes risk among
women.23 A large cross-sectional study including only women residing in Australia, WC
along with WHR and waist-to-height ratio were stronger predictors of CVD risk than
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BMI. WC and WHR were specifically found to be independent predictors of CVD risk
after controlling for BMI.24 Flegal et al. performed a study using data from NHANES
1999-2004 comparing BMI, WC and waist-to-height ratio compared to body fat
percentage. Overall, BMI, WC, and waist-to-height ratio were found to be similar
indicators of body fatness, but are more closely associated with each other than with body
fat percentage.13 With many abdominal obesity measures competing similarly or better
than WC, a combination of obesity measures may be more beneficial in disease risk
assessment.

Waist-to-height Ratio
Many studies support the use of waist-to-height ratio (WHtR) as the ideal
screening tool for cardiometabolic disease and mortality.9,25–28 Unlike other
anthropometric measurements, WHtR factors in height to account for larger/smaller
statures and their associated waist sizes. An ideal WHtR has been suggested to be less
than or equal to 0.5, while a high WHtR would be greater than 0.5. While this is a
common used reference value in research, there is technically no standard reference value
for WHtR. This has led to discussion of whether 0.5 is an acceptable reference value for
whole population, or whether there should be different reference values between gender,
age groups, and ethnicities. Bohr et al. found that 0.58 may be a better reference value in
younger adults in the prediction of risk of metabolic syndrome.29 However, with study
populations that include a wide range of ages, a WHtR reference value of 0.5 is often
used as it appears to be generally accepted in current research.9
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Sagittal Abdominal Diameter
Sagittal abdominal diameter (SAD) has become an increasingly more common
anthropometric measure, as it has been included in the NHANES physiological
measurements since 2011. SAD is measured in the supine position using a caliper
positioned in the center of the abdomen, midway between the left and right iliac crests.
This measures the height of the abdomen, which has been shown to be associated with
the amount of visceral fat in the abdomen. While in the supine position, subcutaneous fat
is believed to fall to the sides of the body leaving mostly visceral fat exposed, possibly
identifying those with higher disease risk. With visceral fat being more correlated with
cardiometabolic disease risk, SAD has become a more attractive screening tool. SAD
does not currently have cut points to establish risk. Several studies have established their
own versions of cut points but no standard has been established. Many studies have
examined SAD and its ability to predict visceral adiposity compared to magnetic
resonance imaging. While several dated studies found SAD unable to predict visceral
adiposity,30,31 most studies have found an advantage to using SAD over the expensive and
radiation-emitting MRI and CT scans.7,32–36

Sagittal Abdominal Diameter-to-Height ratio
While SAD has advantages over WC in measuring visceral fat, it still does not
account for stature. With improvements in assessing risk by factoring height into WC, it
could be assumed that height would improve disease risk assessment with SAD. Only one
study has measured SAD-to-height ratio (SADHtR) against the other anthropometric
measurements. In this study, Kahn and Bullard found that SADHtR was significantly
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better at identifying cardiometabolic risks except for dysglycemia, in which WHtR better
identified dysglycemia.12

Cardiometabolic Risks
Blood Pressure
Based on data from NHANES 2009-2012, over 32 percent of US adult population
has high blood pressure, or hypertension.37 According to the National Heart, Lung, and
Blood Institute, high blood pressure is defined as a systolic blood pressure greater than or
equal to 140 mm Hg or a diastolic blood pressure greater than or equal to 90 mm Hg.
Self-reported use of anti-hypertensive medications was also used to define hypertension
in this study. Left untreated, high blood pressure can lead to heart failure, heart attack,
stroke, and many other complications. With such a high prevalence of blood pressure
within the U.S., it is important to use measurements of obesity that can identify subjects
at risk for hypertension.

Anthropometric Measures and Blood Pressure Risk
Many studies have been conducted observing blood pressure and various
measures of general and abdominal obesity, but only several have been conducted on a
nationally representative adult population, with only one on the U.S. population. A
systematic review by Browning et al. found that WHtR and WC outperformed BMI in
identifying risk of hypertension.9 A meta-analysis by Van Dijk et al. found that WC was
moderately correlated with systolic blood pressure (SBP) and both WC and BMI with
diastolic blood pressure among men and women. For both genders, WC was overall
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significantly more correlated with CVD risk factors, including blood pressure, than BMI.
WHtR was determined to be the least correlated with CVD risk factors. However, this
sample also only consisted of Caucasians from different regions of the world.38 There is
one meta-analysis by Savva et al. that observed a variety of ethnic groups. This analysis
was slightly more comprehensive as its inclusion criteria was for elevated blood pressure,
with a systolic blood pressure of 130 mm Hg or greater and/or a diastolic blood pressure
of 85 mm Hg or greater. They also included participants that reported diagnosis from a
physician or antihypertensive medication use. Based on pooled ratios of relative risk
(rRR), neither BMI nor WHtR outperformed the other in regards to elevated blood
pressure except among Asians, where WHtR was more favored. However, this finding
lost strength once stratified by gender.39

In terms of cross-sectional studies, there are two nationally representative study
samples, one from Australia by Goh et al. and other from the U.S. by Kahn and Bullard.
Goh et al. observed Australian women without a history of heart disease, diabetes or
stroke. Their findings included that waist-to-hip ratio and waist-to-stature ratio (WHtR)
were more correlated with CVD risk, including systolic blood pressure, than BMI and
body adiposity index (BAI: hip circumference divided by height, subtracting 18 from the
result).24 Kahn and Bullard conducted a cross-sectional study that was a nationally
representative of the U.S. adult population. Comprising both genders and a variety of
ethnicities, Kahn and Bullard were able to establish that odds ratios (ORs) adjusted for
age, age-squared, and a quadratic term for each adiposity measure were highest for
SADHtR and lowest for BMI in predicting risk of hypertension. When excluding
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individuals taking antihypertensive drugs, the prevalence of hypertension dropped among
men and women, but remained to be best identified by SADHtR. When competing with
BMI, SADHtR was able to identify those with hypertension while BMI could not.
However, when competing with BMI, neither WHtR nor BMI were able to identify
individuals with hypertension. Of all of the studies mentioned, most found that measures
of abdominal obesity including WC, WHtR, WHR, and SADHtR were better at assessing
risk of high blood pressure than BMI. However, none of the abdominal obesity measures
have been found to be consistently better than one another.12

Pre-Diabetes
According to the Centers for Disease Control and Prevention (CDC), over one
third of the United States adult population has pre-diabetes, equating to about 86 million
adults. Unfortunately, about 90 percent of these individuals are unaware they have prediabetes.40 Along with increased risk of diabetes, pre-diabetes is known to increase risk
of cardiovascular disease, stroke, and all-cause mortality.41 According to the American
Diabetes Association, pre-diabetes is defined as a hemoglobin A1C between 5.7 – 6.4%,
a fasting plasma glucose of 100-125 mg/dL, and/or a two hour blood glucose level of
140-199 mg/dL following an oral glucose tolerance test. With such a high prevalence of
pre-diabetes in the United States, screening methods are needed to identify those at risk
for pre-diabetes.
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Anthropometric Measures and Pre-Diabetes Risk
Most studies that observe blood glucose or hemoglobin A1c levels focus strictly
on diabetes risk rather than pre-diabetes risk. Only two studies comparing abdominal
obesity measures analyzed individuals without a diagnosis of diabetes. One study by
Kahn et al. from 2014 included individuals with diagnosed diabetes in their NHANES
2011-2012 study sample and also included another group of individuals with a
hemoglobin A1c equal to or greater than 5.7%, termed dysglycemia, but without a
diabetes diagnosis. While this group may include those with undiagnosed diabetes, the
efforts are primarily focused on identifying those with pre-diabetes. In this study, they
found that when SAD and BMI quartiles were simultaneously analyzed in the same
model, the prevalence of dysglycemia within the third and fourth quartiles for SAD was
the greatest. Prevalence of dysglycemia was not significantly associated with the third
and fourth quartiles for WC and BMI.8

Another study by Kahn and Bullard in 2016 only included individuals without
diagnosed diabetes in their NHANES 2011-2012 study sample and compared BMI,
WHtR, and SADHtR with risk of dysglycemia, or a hemoglobin A1c of 5.7% or greater.
In simultaneous competition with BMI, neither SADHtR nor BMI were able to identify
individuals with dysglycemia. However, with WHtR in competition with BMI, WHtR
was able to identify dysglycemia while BMI could not. With SADHtR and WHtR in
simultaneous competition, neither was significantly different from one another in
identifying dysglycemia.12
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Diabetes
In the United States, 1 in 10 adults have diabetes, with a majority of cases being
type 2 diabetes.37 The American Diabetes Association defines diabetes as a hemoglobin
A1C greater than or equal to 6.5%, a fasting blood glucose of 126 mg/dL or greater,
and/or a two hour blood glucose level of 200 mg/dL or greater following an oral glucose
tolerance test. With many complications including neuropathy, nephropathy, and
retinopathy, diabetes can also increase risk of high blood pressure, cardiovascular
disease, and stroke.42

Anthropometric Measures and Diabetes Risk
In regards to risk for diabetes, most studies have been conducted observing obese
individuals rather than individuals of all weight statuses. A systematic review by
Browning et al. identified that among prospective and cross-sectional studies, WHtR,
WC, and BMI were equally significant predictors of diabetes in men and women.9 A
meta-analysis by Van Dijk et al. showed that when comparing BMI, WC, WHtR, and
WHR among men, WC had the strongest correlation with fasting blood glucose levels.
WHtR was found to have the weakest correlation with fasting blood glucose. In women,
WC and WHR were similarly correlated to fasting blood glucose, and WHtR was again
the least correlated.39 In a meta-analysis by Savva et al. in 2013, diabetes was identified
as a fasting blood glucose of 126 mg/dL or greater, a two hour post prandial blood
glucose of 200 mg/dL or greater, a physician’s diagnosis of diabetes, and/or use of blood
glucose lowering medications. In this study, the pooled rRR of WHtR and BMI were
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found to be in favor of WHtR in the identification of persons with diabetes in Asians and
non-Asians in cross-sectional studies, and just among Asians in prospective studies.39

Very few cross-sectional studies exist focusing on the general population versus
specific subgroups. A cross-sectional study by Pajunen et al. used Finland’s Health 2000
Survey, focused on participants aged 30 years or older. This study did however consist of
primarily Northern European Caucasians. Using multivariate models to account for
lifestyle factors, it was found that BMI, WC, WHR, and SAD were all significant
predictors of incident diabetes. Pairwise comparisons identified that the combination of a
high BMI and high SAD was associated with the highest incidence of diabetes.43 This
does not come as a surprise, as individuals with a high weight status and a higher
concentration of visceral adipose tissue are already at a high risk for diabetes.

Total Cholesterol
Total cholesterol is a measure of serum LDL cholesterol, HDL cholesterol, and
very low-density lipoprotein (VLDL) cholesterol. Based on NHANES 2009-2012 sample
data, over 100 million US adults over the age of 20 have high total cholesterol (≥200
mg/dL). Of these adults, nearly 31 million have total cholesterol levels of 240 mg/dL or
greater.37 Total cholesterol is inexpensive to measure and does not require a fasted state,
but cannot distinguish between the “good” and “bad” cholesterols. Total cholesterol is
generally used in combination with other lipid measures to profile a complete lipid
profile. High total cholesterol is defined as greater than or equal to 200 mg/dL or selfreported use of lipid-lowering medications.
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Anthropometric Measures and Total Cholesterol Risk
While most studies involving the relationship of anthropometric measures
evaluate total cholesterol, the primary outcomes are generally the incidence of CVD, or
incidence of all cardiovascular events, rather than incidence of high total cholesterol. In a
systematic review by Browning et al., WHtR, WC, and BMI did not differ in their ability
to predict high total cholesterol.9 In a meta-analysis by Van Dijk et al., BMI, WC, and
WHR among men were all similarly correlated with risk of high total cholesterol, with
WHtR ratio only slightly less correlated. With women, WC and WHR were both found to
be significantly better than BMI at predicting risk of high total cholesterol. Again, WHtR
was the least correlated with high total cholesterol risk.38 Savva et al. found through
meta-analysis that WHtR and BMI were not statistically significant in identifying
dyslipidemia among all ethnic groups. WHtR was found statistically significant over BMI
in identifying dyslipidemia among Asian populations, including men and women. It is
important to note that dyslipidemia was used as a primary outcome, which does include
hypercholesterolemia, but also several other abnormal lipid levels including LDL, HDL,
and triglycerides.39 Given the variety of lipid measurements used in this outcome, it may
explain for lack of significance in establishing a superior obesity measure.

HDL Cholesterol
According to CDC statistics from NHANES 2009-2010, about 31 percent of men
and 12 percent of women had low HDL cholesterol in the United States.44 High-density
lipoprotein cholesterol, or HDL cholesterol, is generally known as the “good” cholesterol.
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HDL cholesterol aids in the removal of cholesterol from the body by delivering unused
cholesterol to the liver for removal from the body.45 Higher levels of HDL cholesterol
lower the risk of cardiovascular disease and stroke.21,46 Low HDL cholesterol has the
opposite effect and is defined as less than 40 mg/dL.

Anthropometric Measures and HDL Cholesterol Risk
HDL cholesterol is a very commonly used measurement in current research, most
likely related to its measurement not requiring a fasted state. However, it is generally not
one of the primary outcomes, grouping it together with other cardiometabolic risk factors
in metabolic syndrome or cardiovascular disease research. This has limited the number of
research findings related to HDL cholesterol risk alone. In 2010, a systematic review by
Browning et al. revealed that BMI, WC, and WHtR were all strongly correlated with risk
of low HDL cholesterol.9 Van Dijk et al. found in a meta-analysis that WC and BMI were
almost equally moderately correlated with low HDL risk among men and women, with
higher correlations among women.38

Non-HDL Cholesterol
Non-HDL cholesterol is calculated as the difference between serum total
cholesterol and serum HDL cholesterol. This measurement is thought to be a better
representation of “bad” cholesterol compared to serum total cholesterol, as it measures
LDL cholesterol, and VLDL cholesterol, a transporter of cholesterol and triglycerides
around the body. Based on NHANES 2005-2010 data, the prevalence of high non-HDL
cholesterol among US adults is nearly 28 percent.47 According to the NCEP-III, patients
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with triglycerides above 200 mg/dL should also have their serum non-HDL cholesterol
levels monitored and kept within 30 mg/dL of their LDL cholesterol goal. Based on this
guideline, high non-HDL cholesterol is defined as greater than or equal to 130 mg/dL.
Non-HDL can also be measured in a non-fasted state, making it a quick measure to be
used in screening risk for CVD.

Anthropometric Measures and Non-HDL Cholesterol Risk
A limited number of studies have been conducted comparing anthropometric
measures and their ability to predict high non-HDL risk. A recent study with a similar
design by Kahn et al. compared BMI, WHtR, and SADHtR in their ability to predict five
cardiometabolic disorders, including “HyperNon-HDLc”, or high levels of non-HDL-C.
Using data from NHANES 2011-2012, logistic regression models revealed that
HyperNon-HDLc was best recognized by SADHtR. Among men and women, BMI was
the weakest at predicting HyperNon-HDLc. When analyzed simultaneously, SADHtR
and WHtR were comparable in identifying HyperNon-HDLc.12 These findings support
the hypothesis that abdominal measures of obesity may be stronger predictors of risk than
BMI alone, especially with identifying high non-HDL cholesterol.

Apolipoprotein B
ApoB is a key structural component of all lipoproteins, including LDL, VLDL,
intermediate-density lipoprotein (IDL), chylomicrons, and lipoprotein (a) particles.48
LDL cholesterol molecules tend to be heterogeneous in terms of cholesterol content.
Individuals with a large number of LDL particles with little cholesterol content (or
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small/dense LDL particles) may have the same LDL concentration as an individual with
fewer LDL particles that are high in cholesterol concentration (large, low density LDL
particles). With one ApoB molecule per lipoprotein, ApoB measurements allow
clinicians to distinguish LDL concentrations that may have a variable amount of
cholesterol content.49 High Apo B is defined as a serum ApoB level of 80 mg/DL or
greater, or self-reported use of lipid-lowering medications. Many studies have concluded
that ApoB is a stronger screening tool for CVD than LDL, non-HDL concentrations, or
other lipoprotein ratios 50–54, affirming its use as risk factor for research among normal
weight and overweight individuals.

Anthropometric Measures and ApoB risk
To our knowledge, only one study has been conducted observing ApoB levels
associated with measures of abdominal obesity. In this study by Onat et al.55, a single
scan CT was performed on 157 Turkish participants, aged 34-69 years, in efforts to
measure total adipose tissue area, abdominal visceral adipose tissue (VAT) area, and
sagittal abdominal diameter in association with cardiovascular risk factors. Among the
study population, 34% of participants had metabolic syndrome. Using linear regression
analysis, ApoB and HDL-C were found to be independently associated with VAT area
among men only. They also observed higher VAT areas in men compared to women for
any given waist circumference as well as higher VAT areas in men compared to women
for any given body fat mass. This suggests that men may be prone to a higher waist
circumference thus a higher VAT area while at a lower BMI. With the measurement of
ApoB as a cardiovascular risk factor being a fairly recent concern, more research needs to
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be conducted to support its use as a predictive measure. ApoB has been measured by
NHANES in both 2 year cycles used in this study and also does not require a fasted state
to be measured, making it an ideal measure for use in this study.

Normal Weight/Overweight Risk
Given that obesity status generally has an exponential relationship with
cardiometabolic disorders, it can be assumed that obese individuals are at much higher
risk of developing cardiometabolic disorders than those that are normal weight or
overweight. However, normal weight and overweight individuals may or may not be at as
high of risk depending on the amount of visceral adipose tissue, which is more associated
with disease risk compared to general obesity. In order to identify risk in these
individuals, abdominal obesity measures may need to be compared in order to determine
which can be most beneficial in identifying a variety of risk factors. To date, no studies
have been performed observing a strictly normal weight or overweight population.

National Health and Nutrition Examination Survey
The National Health and Nutrition Examination Survey (NHANES) is an ongoing
nationally representative, cross-sectional survey of the resident civilian, noninstitutionalized, United States population. The survey consists of a home interview
including demographic, socioeconomic, dietary, and health-related questions. The
examination at the mobile examination center (MEC) consists of medical, dental, and
physiological measurements, and various laboratory tests. Visiting 15 counties around the
country per year, NHANES collects data from about 5,000 people per year to develop a
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two-year sample of about 10,000 participants. By oversampling older adults and certain
ethnic groups, researchers can establish significant findings among these populations.56

Until the 2011-2012 NHANES data cycle, SAD measurements had not previously
been collected at the Mobile Examination Center (MEC). However, NHANES has
continued to measure SAD since, allowing for two two-year data cycles to be available
for research using this anthropometric measure. With only one-third of adult participants
being in a fasted state for laboratory measurements, the use of cardiometabolic risk
measurements that require a fasted state significantly lowers the study population. The
use of laboratory measures that do not require a fasted state allow for the use of all
subjects examined and tested at the MEC.
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CHAPTER III

JOURNAL ARTICLE

RESEARCH SNAPSHOT
Research Question: Are abdominal obesity measures more strongly associated with
cardiometabolic risk than BMI, particularly in normal and overweight adults? And does
height improve the ability of abdominal obesity measures to assess cardiometabolic risk?

Key Findings: In this cross-sectional, nationally representative study that included 6482
normal weight and overweight adults from the National Health and Nutrition
Examination Survey of 2011-2014, body mass index could only identify risk of low highdensity lipoprotein cholesterol, while waist-to-height ratio, sagittal abdominal diameter,
and sagittal abdominal diameter-to-height ratio identified six out of seven
cardiometabolic risks.
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ABSTRACT
Background: It has been well established that screening tools for cardiometabolic
diseases are less useful among obese populations as risk of these diseases is already high.
However, research is lacking in regard to efficient screening tools for cardiometabolic
diseases among normal weight and overweight populations.
Objective: This study compared the predictive strengths of body mass index (BMI),
waist circumference (WC), waist-to-height ratio (WHtR), sagittal abdominal diameter
(SAD), and SAD-to-height ratio (SADHtR) with respect to risk of cardiometabolic
disorders in normal and overweight U.S. populations.
Design: This cross-sectional study utilized data from the 2011-2014 National Health and
Nutrition Examination Survey.
Participants/setting: The sample included non-pregnant adults with a normal weight or
overweight BMI status (≥ 20 years; n = 6482).
Main outcome measures: Each anthropometric measure was assessed for predicting risk
of the following cardiometabolic disorders: hypertension (HTN), pre-diabetes, diabetes,
high total cholesterol, low high-density lipoprotein cholesterol (HDL-C), high non-HDLC, and high apolipoprotein B.
Statistical analyses performed: Simple and multiple logistic regression analyses
compared the odds ratio of each anthropometric measure for each cardiometabolic
disorder.
Results: When analyzed in separate models, BMI, WC, WHtR, SAD, and SADHtR
identified all cardiometabolic risks. In simultaneous models with abdominal obesity
measures, BMI no longer identified cardiometabolic risks (ORs <1.0), except low HDL-
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C. Among normal weight and overweight men, WHtR and SADHtR were stronger
measures of cardiometabolic risk except low HDL-C. With normal weight and
overweight women, WHtR and SADHtR were stronger measures of risk for hypertension
and diabetes, while all of the abdominal obesity measures were similar in assessment of
the remaining cardiometabolic risks.
Conclusion: In normal weight and overweight adults, anthropometric measures of
abdominal obesity, especially those including a factor of height, are better predictors of
cardiometabolic risk than BMI and should be a primary screening tool in this population.
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INTRODUCTION/BACKGROUND
While obesity rates in the United States (U.S.) have started to plateau based on
body mass index (BMI) measurements, abdominal obesity rates are on the rise according
to measures of waist circumference.1,2 Abdominal obesity, as compared with other
distributions of adipose tissue, has specifically been shown to be highly associated with
chronic diseases such as diabetes, cardiovascular diseases, and other cardiometabolic
diseases.3–5
BMI has traditionally been used for the assessment of body weight but has been
shown to lack accuracy in terms of body composition. Waist circumference (WC), waistto-height ratio (WHtR), and sagittal abdominal diameter (SAD) are several measures that
are used in assessing abdominal obesity, with SAD being a relatively newer measure.
SAD is measured in the supine position using a caliper positioned in the center of the
abdomen, midway between the left and right iliac crests, measuring the height of the
abdomen, which has been shown to be associated with the amount of visceral fat in the
abdomen. Since SAD measurements only require the use of a specialized caliper, this
allows for the measurement to be easy, fast, and inexpensive compared to the more
precise yet radiation-emitting magnetic resonance imaging and dual-energy x-ray
absorptiometry.
To date, a limited number of large-scale studies have been conducted evaluating
SAD with various cardiometabolic risks in the U.S. adult population. A study in 2005 by
Smith et al. found among men that SAD was a stronger predictor of coronary heart
disease risk when divided by thigh circumference, known as the abdominal diameter
index.6 In 2013, Gletsu-Miller et al. found that SAD was stronger at predicting levels of
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visceral adipose tissue, and thus the ability to predict risk of dysglycemia, than WC after
controlling for confounding variables among a small sample of severely obese women.7
Similarly, in 2014, Kahn et al. found that SAD was associated with dysglycemia among
men and women independently from WC and BMI in a nationally representative sample
of the U.S. population.8 These findings suggest that SAD may be a useful screening tool
in the U.S. population among men and women.
Since WHtR has often been shown to be a better measure of abdominal obesity
than WC alone, it is logical to expect that SAD may be more effectively used as the
SAD-to-height ratio (SADHtR).9,10 Few studies have investigated the relationship
between metabolic risks and SADHtR, with only two studies having been conducted in
the U.S. population. One of the studies focused on various abdominal measures and their
associations with sex, age, socioeconomic status, and ethnicity, rather than comparing
efficacy of abdominal obesity measures.11 The second study compared several
anthropometric measures, including SAD and SADHtR, against cardiometabolic risks in
a nationally representative sample of the U.S. population using National Health and
Nutrition Examination Survey (NHANES) 2011-2012 data. In that study, Kahn et al.
found that SADHtR and WHtR were better at predicting risk of cardiometabolic disorders
than BMI12; suggesting that SADHtR may be a better screening tool, especially compared
to BMI.
Current disease-related research focuses primarily on the whole population,
including obese individuals. However, obese populations are already at a high risk of
developing obesity-related diseases making abdominal obesity measures relatively
unimportant. When determining a useful screening tool for obesity-related diseases, it is
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important to find a tool that also works well in normal weight and overweight
populations. In some studies, an overweight status has been suggested to be protective,
especially among older adults.13,14 However, recent research suggests that an overweight
BMI status based on highest lifetime BMI is associated with increased risk of
cardiovascular and all-cause mortality.15 This implies the need for an abdominal obesity
measure among normal weight and overweight populations that may predict disease risk
before the development of the disease occurs. Therefore, the objectives of this study
include: 1) to compare the predictive strengths of BMI, WC, WHtR, SAD, and SADHtR
with respect to risk of cardiometabolic disorders in the normal and overweight U.S. adult
population; 2) to compare WC against WHtR, and SAD against SADHtR ratio to
determine whether height improves the predictive strengths; and 3) to compare WC
against SAD and WHtR and SADHtR to determine which provides the strongest
predictive strength of cardiometabolic disorders. It is hypothesized that abdominal
obesity measures will be stronger than BMI in cardiometabolic risk prediction and that
the inclusion of height with these measures will only strengthen their ability to assess
risk.

METHODS

Study Population and Analytic Sample
The NHANES is an ongoing nationally representative, cross-sectional survey of
the resident civilian, non-institutionalized, U.S. population. The survey consists of a
home interview including demographic, socioeconomic, dietary, and health-related
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questions. The examination at the mobile examination center (MEC) consists of medical,
dental, and physiological measurements, as well as various laboratory tests.16 Several
subgroups are oversampled, including Hispanics, non-Hispanic Asians, non-Hispanic
blacks, and non-Hispanic whites over 80 years of age. Given this oversampling, sample
weights are used to develop a distribution that is representative of the U.S. population.17
Data from the NHANES 2011-2012 and 2012-2014 datasets were used to
evaluate associations between various measurements of abdominal obesity and
cardiometabolic risk factors. Participants consisted of male and female adults of all
ethnicities, aged 20+ years who participated in both the home interview and physical
examination components of NHANES. Two samples were examined for this study, one
consisting of the whole adult population (n = 10,723) stratified by gender and the other
consisting of only adult participants with a normal weight or overweight BMI status (n =
6482), also stratified by gender. Females who were pregnant or lactating were excluded
from this study as well as participants with missing values for any of the anthropometric
and/or laboratory tests.

Anthropometric and Physiologic Measurements
Height, weight, WC, and SAD were measured according to NHANES protocols.18
WHtR and SADHtR were calculated using the above measurements. Measurements of
cardiometabolic risk included blood pressure, hemoglobin A1C, total cholesterol, highdensity lipoprotein-cholesterol (HDL-C), non-HDL-C, and Apoliprotein B (ApoB).
These measures were chosen in part because they did not required a fasted blood sample
and thus allowed for a greater sample size. Descriptions of the examination and
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laboratory methods used in this study are described in online NHANES documentation.19
HTN was defined as having a blood pressure of 140/90 mm Hg or greater20, or selfreported use of an anti-hypertensive medication. Pre-diabetes was defined as a having a
hemoglobin A1C of 5.7-6.4%, while diabetes was defined as a hemoglobin A1C of 6.5%
or greater21, or self-reported use of insulin or a blood glucose lowering medication. High
total cholesterol was defined as having a serum total cholesterol level of 200 mg/dL or
greater, or self-reported use of a lipid lowering medication. Low HDL-C was defined as
having a serum HDL-C level of less than 40 mg/dL.22 High non-HDL-C risk was defined
as having a serum non-HDL-C level of 130 mg/dL or greater, or self-reported use of a
lipid lowering medication. Lastly, high ApoB was defined as having a serum ApoB level
of 80 mg/dL or greater, or self-reported use of a lipid lowering medication.

Statistical Analysis
Weighted data was used in all statistical analyses using Statistical Analysis
Software (SAS System version 9.2, SAS Institute Inc., Cary, North Carolina, USA).
Simple logistic regression was performed to estimate the magnitude of the association
between each anthropometric measurement with each cardiometabolic risk factor.
Subjects were divided into quartiles based on each anthropometric measurement for
determination of the odds ratios (ORs) for each cardiometabolic risk factor. The ORs of
the first quartile, the reference group, was compared to the ORs of the fourth quartile to
determine the strength of each measurement in the prediction of cardiometabolic risk. Ttests were used to establish significant differences between the ORs for BMI and all other
abdominal obesity measures for each cardiometabolic risk. Because of the large number
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of comparisons being made, a P-value of less than 0.01 was considered to be statistically
significant.
To identify whether abdominal obesity measures were significantly different from
one another in their predictive strength, we conducted multiple logistic regression
analysis to simultaneously compare BMI with measures of abdominal obesity. Four
models were used per cardiometabolic risk: BMI, WC, and WHtR; BMI, SAD, and
SADHtR; BMI, WC, and SAD; and BMI, WHtR, and SADHtR. Significant differences
were identified for measurements whose 95% confidence intervals (CI) did not overlap.
For measurements that only had slight overlap of 95% CI, t-tests were performed to
establish significant differences.

RESULTS
The quartile cut-points for each anthropometric measurement for both the entire
adult population and for just the normal weight and overweight population can be found
in Table 1. The ORs of the fourth quartile compared to the first quartile of each
cardiometabolic risk based on each anthropometric measurement for the adult male
sample and the normal weight or overweight adult male sample are shown in Table 2.
The ORs for all anthropometric measures were significantly greater in the fourth quartile
than the first quartile for BMI and each measure of abdominal obesity for every
cardiometabolic risk. While the data are not shown, it is also important to note that ORs
consistently increased for with each quartile for each obesity measurement for all of the
cardiometabolic risks.
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Table 1. Means and quartile cut points based on gender for the NHANES 2011-2014 data
sample.

25p

BMI, kg/m2
WC, cm
WHtR
SAD, cm
SADHtR

All
24.2
89.1
0.51
19.4
0.114

NW/
OW
23.3
86.0
0.49
19.1
0.110

Quartile Cut Points: All Adults & N/OW Adults
Males
Females
50p
75p
25p
50p
75p
NW/
NW/
NW/
NW/
NW/
All OW
All OW
All OW
All OW
All OW
27.4
25.5
31.3
27.6
23.8
22.4
28.2
24.8
33.7
27.3
99.0
93.2 109.2 100.0
84.7
80.5
95.5
87.2 107.4
94.0
0.56
0.54
0.62
0.57
0.52
0.50
0.59
0.54
0.67
0.59
22.2
21.1
25.5
23.0
20.0
17.6
22.7
19.4
25.8
21.3
0.130 0.121 0.147 0.133 0.117 0.110 0.135 0.121 0.157 0.133

N/OW: normal and overweight, BMI: Body mass index, WC: Waist circumference, WHtR: Waist-to-height
ratio, SAD: Sagittal abdominal diameter, SADHtR: SAD-to-height ratio.

Among all adult males, BMI was significantly weaker than most measures of
abdominal obesity for predicting risk of HTN, diabetes, and high total cholesterol. There
were no significant differences between BMI and measures of abdominal obesity for
predicting risk of low HDL-C, high non HDL-C, and high ApoB. Similarly, among
normal and overweight adult males, most measures of abdominal obesity were
statistically stronger than BMI at predicting risk of HTN, pre-diabetes, diabetes, and high
total cholesterol.

Table 2. Simple logistic regression analysis of cardiometabolic risks by each
anthropometric measurement for all adult males and normal weight or overweight males
of the NHANES 2011-2014 sample.
Risk

HTN

Pre-DM

Measure
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR

All Adult Males
Odds Ratio
95% CI
3.69
2.84 - 4.79
6.93
5.17 - 9.30a
8.42
6.27 - 11.31a
7.41
5.47 - 10.05a
8.06
6.03 - 10.77a
1.78
1.30 - 2.42
2.55
1.87 - 3.47
2.69
1.98 - 3.65
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NW/OW Males
Odds Ratio
95% CI
2.31
1.73 - 3.07
7.32
5.51 - 9.71a
10.57
7.64 - 14.62a
7.04
4.66 - 10.64a
9.48
6.35 - 14.18a
1.84
1.31 - 2.58
2.95
2.22 - 3.92
3.95
2.73 - 5.71a

DM

High TC

Low HDL

High
Non-HDL

High ApoB

SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR

3.01
3.06
6.7
12.95
19.09
15.08
23.48
2.43
3.68
3.98
4.02
3.84
5.17
5.45
4.49
6.28
5.87
4.02
5.41
5.71
5.82
5.62
4.06
5.18
5.31
5.51
5.09

2.29 - 3.96a
2.30 - 4.09a
4.35 - 10.33
8.28 - 20.24
9.97 - 36.57a
9.31 - 24.41a
11.63 - 47.43a
1.89 - 3.12
2.72 - 4.96
2.92 - 5.41a
3.06 - 5.28a
2.94 - 5.01a
3.87 - 6.90
4.26 - 6.98
3.45 - 5.83
4.92 - 8.02
4.45 - 7.74
3.18 - 5.08
4.15 - 7.06
4.35 - 7.51
4.56 - 7.41
4.20 - 7.52
2.84 - 5.81
3.29 - 8.16
3.47 - 8.12
3.79 - 8.02
3.19 - 8.10

3.45
3.96
2.45
8.35
15.71
11.58
14.29
2.38
5.60
6.36
4.84
6.00
4.19
3.43
3.23
4.67
5.05
3.93
7.00
7.07
6.51
7.48
2.96
4.60
6.23
4.80
6.97

2.27 - 5.27
2.72 - 5.76a
1.60 - 3.76
4.51 - 15.46a
7.51 - 32.87a
5.30 - 25.32a
6.52 - 31.30a
1.80 - 3.16
3.96 - 7.93a
4.41 - 9.16a
3.62 - 6.48a
4.39 - 8.19a
2.88 - 6.08
2.46 - 4.79
2.32 - 4.51
3.16 - 6.89
3.38 - 7.55
2.94 - 5.24
5.15 - 9.53
5.16 - 9.70
4.96 - 8.56
5.69 - 9.83a
1.95 - 4.48
2.97 - 7.15
3.85 - 10.09
3.19 - 7.21
4.78 - 10.17a

NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM:
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein;
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio,
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio.
Odds ratios represent Quartile 4 compared to Quartile 1.
a
Denotes significant difference from BMI (≤0.0001 P < 0.01)

Table 3 reports the ORs of the fourth quartile compared to the first quartile of
each cardiometabolic risk based on each anthropometric measurement for the adult
female sample and the normal weight or overweight adult female sample by simple
logistic regression. Among all adult females, BMI was significantly weaker than most
abdominal obesity measures for predicting risk of HTN, diabetes, high non-HDL-C, and
high total cholesterol. There were no differences between abdominal obesity measures
and BMI with the risk assessment of low HDL-C and high ApoB. Among the normal
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weight and overweight female sample, abdominal obesity measures were stronger than
BMI when predicting risk for HTN, high, total cholesterol, high non-HDL-C, and high
ApoB. There were no differences between abdominal obesity measures and BMI related
to risk of pre-diabetes and low HDL-C.

Table 3. Simple logistic regression analysis of cardiometabolic risks by each
anthropometric measurement for all adult females and normal weight or overweight
females of the NHANES 2011-2014 sample.
Risk

HTN

Pre-DM

DM

High TC

Low HDL

High
Non-HDL

High ApoB

Measure
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC
WHtR
SAD
SADHtR
BMI
WC

All Adult Females
Odds Ratio
95% CI
3.32
2.63 - 4.18
5.07
3.89 - 6.60a
7.03
5.02 - 9.86a
7.00
5.44 - 8.98a
8.00
6.22 - 10.29a
2.72
2.10 - 3.52
2.8
2.08 - 3.77
3.73
2.75 - 5.05
3.04
2.08 - 4.43
3.55
2.49 - 5.06
9.44
6.62 - 13.46
14.93
10.27 - 21.71b
32.23
20.58 - 50.48a b
21.24
12.66 - 35.64a
26.49
15.99 - 43.89a
1.75
1.42 - 2.16
2.36
1.87 - 2.96
2.73
2.15 - 3.45a
2.46
1.99 - 3.03
2.53
2.06 - 3.11a
7.73
4.72 - 12.67
11.91
7.29 - 19.45
12.21
6.62 - 22.53
10.30
5.49 - 19.33
9.3
5.11 - 16.92
3.22
2.68 - 3.87
4.26
3.38 - 5.38
4.99
3.96 - 6.29a
4.66
3.82 - 5.69a
4.75
3.98 - 5.66a
3.25
2.41 - 4.37
4.16
3.08 - 5.62
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NW/OW Females
Odds Ratio
95% CI
1.92
1.30 - 2.86
4.95
3.27 - 7.48a
7.46
4.81 - 11.55a
8.90
6.01 - 13.19a
11.19
7.15 - 17.52a
2.47
1.63 - 3.74
5.05
3.46 - 7.36
5.16
3.17 - 8.40
4.20
2.62 - 6.75
4.80
3.02 - 7.64
3.90
2.62 - 5.81
14.77
8.45 - 25.83
36.01
13.59 - 95.47
15.98
8.27 - 30.86
30.61
11.09 - 84.49
2.04
1.52 - 2.73
3.40
2.62 - 4.42
3.93
3.00 - 5.14a
4.46
3.46 - 5.75a
4.69
3.56 - 6.17a
6.13
3.70 - 10.14
8.32
3.04 - 22.74
11.73
4.09 - 33.66
10.35
5.75 - 18.63
9.00
3.79 - 21.40
3.12
2.29 - 4.27
4.90
3.62 - 6.62
6.06
4.38 - 8.37a
6.13
4.66 - 8.05a
6.97
5.17 - 9.40a
2.80
1.97 - 3.99
4.67
3.17 - 6.87

WHtR
SAD
SADHtR

4.39
4.88
4.87

3.34 - 5.77
3.44 - 6.92
3.69 - 6.43

8.47
6.85
7.24

5.43 - 13.22
4.85 - 9.66
5.10 - 10.27

NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM:
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein;
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio,
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio.
Odds ratios represent Quartile 4 compared to Quartile 1.
a
Denotes significant difference from BMI (≤0.0001 P < 0.01)
b
Denotes significant difference between WC and WHtR (P <0.01)

Table 4 shows results of multiple logistic regression analysis for all adult males,
and separately for normal weight and overweight males, with the OR of quartile four
compared to quartile one. When used in simultaneous models with abdominal obesity
measures, BMI was no longer able to identify any of the cardiometabolic risks (ORs <
1.0), except low HDL-C (ORs = 1.80 - 3.14), among all male adults, and normal weight
and overweight male adults. With all adult males, WHtR outperformed WC in the
prediction of risk for four out of seven cardiometabolic risks, while WHtR and WC were
equally stronger predictors than BMI for two out of seven cardiometabolic risks.
SADHtR only outperformed SAD in predicting risk of diabetes, while SAD and SADHtR
were equal predictors of risk for four out of seven cardiometabolic risks. SAD was a
stronger predictor than WC in risk for two out of seven cardiometabolic risks, while SAD
and WC were similar predictors of risk for five out of seven cardiometabolic risks. WHtR
and SADHtR were similar predictors of all cardiometabolic risks except for low HDL-C.
In terms of risk of low HDL-C, BMI and WC were equally stronger predictors than
WHtR. BMI and SAD were also equally stronger predictors of low-HDL-C than WC.
BMI and SADHtR were similar predictors for risk of low-HDL-C compared to WHtR.
With normal weight and overweight adult males, WHtR was stronger than WC in
the prediction of risk for five out of seven cardiometabolic risks, while WC and WHtR
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were similar predictors of risk for high non-HDL-C. SADHtR was a better predictor than
SAD for risk of all cardiometabolic risks except for low HDL-C. SAD was a stronger
predictor than WC in the assessment of risk for diabetes, while SAD and WC were
similar predictors for all remaining cardiometabolic risks except low HDL-C. SADHtR
was stronger than WHtR in the prediction of risk for high ApoB, while SADHtR and
WHtR were similar predictors of risk for all other cardiometabolic risks except low HDLC. For risk of low HDL-C, BMI and SAD outperformed WC, and BMI and SADHtR
outperformed WHtR in the assessment of low HDL-C risk.

Table 4. Multiple logistic regression analysis of cardiometabolic risks by each
anthropometric measurement for all adult males and normal weight or overweight males
of the NHANES 2011-2014 sample.
Risk

HTN

PreDM

Measure
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR

All Adult Males
Odds Ratio
95% CI
0.20
0.12 - 0.33
3.20
1.51 - 6.77a
12.19
6.19 - 23.99a
0.31
0.17 - 0.56
3.81
1.82 - 7.96a
6.59
3.43 - 12.66a
0.27
0.14 - 0.50
4.29
2.15 - 8.54a
6.41
3.21 - 12.80a
0.22
0.13 - 0.37
7.62
4.53 - 12.82a
4.89
2.90 - 8.24a
0.30
0.19 - 0.48
1.35
0.74 - 2.46ab
5.76
3.08 - 10.79ab
0.30
0.19 - 0.47
2.09
1.02 - 4.28a
4.25
2.16 - 8.37a
0.36
0.22 - 0.57
1.40
0.75 - 2.62ad
5.12
2.70 - 9.70ad
0.24
0.15 - 0.39
2.34
1.18 - 4.64a
4.27
2.22 - 8.22a
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NW/OW Males
Odds Ratio
95% CI
0.24
0.14 - 0.41
2.00
1.01 - 3.96ab
17.42
9.29 - 32.67ab
0.35
0.21 - 0.59
1.56
0.79 - 3.09ac
13.57
6.81 - 27.06ac
0.35
0.20 - 0.62
4.48
2.30 - 8.74a
4.66
2.33 - 9.32a
0.21
0.13 - 0.36
8.25
4.34 - 15.68a
5.39
2.68 - 10.84a
0.47
0.30 - 0.75
1.04
0.52 - 2.07b
6.39
2.95 - 13.85ab
0.58
0.40 - 0.85
1.16
0.51 - 2.65
5.26
2.58 - 10.73a
0.61
0.37 - 0.99
1.93
1.09 - 3.43a
2.71
1.38 - 5.34a
0.42
0.28 - 0.64
3.39
1.73 - 6.68a
2.55
1.43 - 4.55a

DM

High
TC

Low
HDL

High
NonHDL

High

BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI

0.26
2.14
31.88
0.32
2.03
31.43
0.37
3.01
13.32
0.21
6.43
16.12
0.27
2.32
5.77
0.36
3.58
2.96
0.32
2.47
4.89
0.28
4.78
2.79
3.14
2.43
0.8
1.89
1.76
2.16
2.35
0.85
3.61
3.03
0.36
6.13
0.54
2.13
5.01
0.60
2.93
3.50
0.57
2.09
5.08
0.51
3.29
3.56
0.58

0.14 - 0.46
0.85 - 5.36ab
10.35 - 98.17ab
0.17 - 0.59
0.74 - 5.61ac
9.18 - 107.55ac
0.21 - 0.67
1.31 - 6.93a
5.61 - 31.59a
0.12 - 0.37
3.15 - 13.11a
7.44 - 34.92a
0.19 - 0.39
1.35 - 4.00a
3.13 - 10.64a
0.24 - 0.54
1.99 - 6.45a
1.66 - 5.29a
0.23 - 0.45
1.39 - 4.39a
2.65 - 9.04a
0.19 - 0.42
2.70 - 8.47a
1.65 - 4.71a
2.21 - 4.45
1.32 - 4.46
0.40 - 1.58a
1.31 -2.74
1.03 - 3.00
1.15 - 4.05
1.63 - 3.40
0.54 - 1.33ad
2.24 - 5.82d
2.06 - 4.45
0.18 - 0.71ae
3.13 - 11.98e
0.33 - 0.91
1.14 - 3.99a
2.31 - 10.85a
0.38 - 0.94
1.55 - 5.55a
1.71 - 7.14a
0.38 - 0.87
1.18 - 3.73a
2.86 - 9.04a
0.29 - 0.88
1.72 - 6.27a
2.08 - 6.08a
0.26 - 1.29
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0.23
1.13
44.85
0.26
1.97
22.44
0.36
2.30
13.26
0.18
8.54
9.60
0.35
2.84
5.55
0.5
1.47
6.747
0.42
4.67
2.55
0.35
4.32
3.79
2.87
1.42
1.14
1.80
1.87
1.93
2.44
0.52
4.55
2.51
0.43
5.44
0.73
2.69
3.71
0.91
1.55
5.35
0.79
3.28
2.85
0.73
2.46
4.33
0.58

0.13 - 0.41
0.52 - 2.46ab
20.08 - 100.16ab
0.15 - 0.47
0.54 - 7.11ac
6.78 - 74.23ac
0.20 - 0.65
0.96 - 5.50ad
4.96 - 35.43ad
0.10 - 0.32
2.74 - 26.66a
3.19 - 28.90a
0.22 - 0.55
1.79 - 4.50ab
3.02 - 10.20ab
0.33 - 0.76
0.99 - 2.19ac
4.08 - 11.16ac
0.29 - 0.62
2.66 - 8.21a
1.66 - 3.92a
0.21 - 0.59
2.34 - 7.97a
2.37 - 6.04a
1.65 - 5.01
0.70 - 2.91
0.59 - 2.18
1.12 - 2.89
0.89 - 3.94
0.88 - 4.22
1.38 - 4.31
0.25 - 1.07d
2.48 - 8.33d
1.53 - 4.13
0.24 - 0.80e
2.92 - 10.17e
0.45 - 1.20
1.58 - 4.57a
1.84 - 7.44a
0.57 - 1.44
0.85 - 2.83
2.62 - 10.93a
0.53 - 1.19
1.96 - 5.52a
1.88 - 4.33a
0.41 - 1.29
1.41 - 4.31a
2.89 - 6.48a
0.27 - 1.24

ApoB

WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR

1.37
6.81
0.66
2.17
3.82
0.72
1.6
4.96
0.5
3.57
2.93

0.48 - 3.91
2.74 - 16.91a
0.33 - 1.30
0.87 - 5.41
1.26 - 11.58
0.36 - 1.45
0.53 - 4.89
1.99 - 12.39a
0.24 - 1.03
1.35 - 9.43a
1.04 - 8.24a

2.36
4.33
0.70
1.38
6.89
0.57
2.92
3.01
0.55
2.51
5.60

1.18 - 4.71
1.96 - 9.59a
0.39 - 1.26
0.66 - 2.90c
3.50 - 13.56ac
0.29 - 1.12
1.27 - 6.73a
1.53 - 5.89a
0.26 - 1.14
0.99 - 6.34
3.04 - 10.30a

NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM:
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein;
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio,
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio.
Odds ratios represent Quartile 4 compared to Quartile 1.
a
Denotes significant difference from BMI (≤0.0001 P < 0.01), b Denotes significant difference between
WC and WHtR, c Denotes significant difference between SAD and SADHtR, d Denotes significant
difference between WC and SAD, e Denotes significant difference between WHtR and SADHtR.

The results of multiple logistic regression analysis for all adult females, and
normal weight and overweight females are reported in Table 5. The OR of quartile four
was compared to the OR of quartile one. In simultaneous models with abdominal obesity
measures, BMI was not able to identify any of the cardiometabolic risks (ORs < 1.0),
except low HDL-C (ORs = 0.77-1.92), among all adult females as well as normal weight
and overweight females. Among all adult females, WHtR is a stronger predictor than WC
for four out of seven cardiometabolic risks, while WHtR and WC are similar predictors
for two out of seven cardiometabolic risks. SADHtR is stronger than SAD in the
prediction of all cardiometabolic risks except low HDL-C. SAD is a stronger predictor
than WC for risk of HTN and pre-diabetes, while SAD and WC are similar predictors for
risk of four out of seven cardiometabolic risks. SADHtR is stronger than WHtR in the
risk assessment of HTN, while SADHtR and WHtR are similar predictors of risk for all
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other cardiometabolic risks except low HDL-C. For risk of low HDL-C, WHtR was
stronger than BMI and WHtR was stronger than BMI when in a model with SADHtR.
With normal weight and overweight adult females, WHtR was a stronger
predictor than WC for five out seven cardiometabolic risks, while WHtR and WC were
similar predictors of risk for pre-diabetes. SADHtR was a stronger predictor of risk than
SAD for HTN and diabetes, while SADHtR and SAD were similar predictors of four out
of seven cardiometabolic risks. SAD was a better predictor than WC for two out of seven
cardiometabolic risks, while SAD and WC were similar predictors of risk for all
remaining cardiometabolic risks except low HDL-C. SADHtR and WHtR were similar
predictors of risk for all cardiometabolic risks except low HDL-C. With risk of low HDLC, there were no significant differences between all measures for each comparison model.

Table 5. Multiple logistic regression analysis of cardiometabolic risks by each
anthropometric measurement for all adult females and normal weight or overweight
females of the NHANES 2011-2014 sample.
Risk

HTN

Pre-DM

Measure
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR

All Adult Females
Odds Ratio
95% CI
0.19
0.13 - 0.29
1.93
1.01 - 3.68ab
17.17
9.23 - 31.93ab
0.13
0.08 - 0.20
3.68
2.04 - 6.64ac
13.97
7.54 - 25.89ac
0.15
0.10 - 0.23
2.13
1.21 - 3.75ad
18.83
11.50 - 30.84ad
0.11
0.07 - 0.17
4.45
2.71 - 7.30ae
15.93
10.09 - 25.15ae
0.74
0.46 - 1.20
0.89
0.54 - 1.48b
5.29
2.98 - 9.38ab
0.61
0.38 - 0.98
0.90
0.39 - 2.05c
5.98
2.84 - 12.58ac
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NW/OW Females
Odds Ratio
95% CI
0.18
0.09 - 0.35
1.41
0.65 - 3.09ab
21.64
10.23 - 45.80ab
0.16
0.08 - 0.33
2.79
1.08 - 7.22ac
17.92
7.56 - 42.45ac
0.19
0.10 - 0.37
2.11
1.27 - 3.51ad
16.5
8.76 - 31.07ad
0.12
0.06 - 0.22
4.80
2.22 - 10.38a
14.77
7.48 - 29.15a
0.47
0.27 - 0.80
2.81
1.69 - 4.66a
4.7
1.97 - 11.23a
0.63
0.39 - 1.02
2.37
1.08 - 5.21a
3.24
1.49 - 7.04a

DM

High TC

Low HDL

High
Non-HDL

BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI

0.8
1.1
3.41
0.49
1.78
4.26
0.29
1.14
88.24
0.43
1.96
29.93
0.4
3.91
14.12
0.18
22.66
9.06
0.27
1.78
5.06
0.28
1.55
5.31
0.27
2.35
3.74
0.21
2.78
4.39
0.77
3.32
5.55
1.28
4.44
2.06
0.81
5.03
3.76
0.86
8.47
2.05
0.44
1.79
6.09
0.46
1.65
6.40
0.45

0.47 - 1.34
0.67 - 1.83d
1.86 - 6.26ad
0.29 - 0.81
0.92 - 3.46e
2.23 - 8.15e
0.15 - 0.55
0.45 - 2.87b
32.92 - 236.52ab
0.23 - 0.83
0.69 - 5.57c
11.19 - 80.03ac
0.21 - 0.79
1.37 - 11.19a
4.28 - 46.56a
0.10 - 0.32
7.98 - 64.34a
3.15 - 26. 04a
0.16 - 0.46
1.15 - 2.75ab
3.11 - 8.24ab
0.18 - 0.45
0.89 - 2.68ac
2.96 - 9.54ac
0.17 - 0.44
1.46 - 3.78a
2.56 - 5.46a
0.12 - 0.37
1.72 - 4.49a
3.10 - 6.22a
0.40 - 1.48
1.26 - 8.76
1.75 - 17.59a
0.61 - 2.71
1.11 - 17.74
0.70 - 6.05
0.39 - 1.70
2.12 - 11.94a
1.25 - 11.30
0.43 - 1.74
3.42 - 20.98a
1.01 - 4.19
0.28 - 0.70
1.10 - 2.93ab
3.56 - 10.41ab
0.30 - 0.70
0.88 - 3.11ac
3.63 - 11.29ac
0.30 - 0.67
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0.52
3.08
3.47
0.51
3.67
3.15
0.2
1.27
107.46
0.39
0.91
68.24
0.34
8.69
7.01
0.17
32.71
7.76
0.43
1.54
4.99
0.45
2.34
3.80
0.43
1.8
4.73
0.36
2.69
3.98
1.30
1.46
7.29
1.92
3.02
2.72
1.53
2.40
3.92
1.28
6.68
1.9
0.61
1.33
6.63
0.64
1.69
5.88
0.65

0.32 - 0.85
1.97 - 4.81a
2.03 - 5.93a
0.29 - 0.88
1.71 - 7.88a
1.89 - 5.25a
0.11 - 0.36
0.51 - 3.15ab
26.58 - 434.49ab
0.17 - 0.90
0.23 - 3.58c
12.05 - 386.60ac
0.18 - 0.65
3.29 - 22.96a
2.33 - 21.14a
0.10 - 0.31
5.90 - 181.22a
1.53 - 39.40a
0.27 - 0.67
0.93 - 2.55ab
2.77 - 8.96ab
0.28 - 0.74
1.44 - 3.79a
2.10 - 6.90a
0.27 - 0.68
1.07 - 3.04a
2.82 - 7.94a
0.22 - 0.59
1.46 - 4.95a
2.20 - 7.22a
0.63 - 2.68
0.44 - 4.86
2.09 - 25.20
0.95 - 3.90
0.70 - 13.06
0.60 - 12.28
0.74 - 3.18
0.92 - 5.90
1.30 - 11.82
0.66 - 2.50
1.62 - 27.58
0.57 - 6.33
0.40 - 0.92
0.82 - 2.17b
3.76 - 11.69ab
0.38 - 1.07
1.07 - 2.65ac
3.51 - 9.85ac
0.42 - 1.00

High
ApoB

WC
SAD
BMI
WHtR
SADHtR
BMI
WC
WHtR
BMI
SAD
SADHtR
BMI
WC
SAD
BMI
WHtR
SADHtR

2.43
4.60
0.32
3.04
5.34
0.45
2.00
4.67
0.4
1.82
6.57
0.4
2.01
6.11
0.32
2.14
6.87

1.42 - 4.18a
2.77 - 7.62a
0.20 - 0.53
1.87 - 4.92a
3.80 - 7.50a
0.22 - 0.94
0.89 - 4.49
1.83 - 11.89a
0.19 - 0.82
0.48 - 6.84
2.12 - 20.37a
0.19 - 0.81
1.07 - 3.76ad
2.67 - 13.97ad
0.14 - 0.74
0.99 - 4.60a
3.58 - 13.21a

1.86
4.64
0.47
2.86
4.68
0.54
0.90
13.41
0.49
2.10
5.97
0.58
1.20
7.98
0.37
4.32
4.65

1.06 - 3.25a
2.73 - 7.88a
0.29 - 0.77
1.45 - 5.65a
2.48 - 8.85a
0.28 - 1.03
0.37 - 2.17b
6.88 - 26.15ab
0.25 - 0.95
0.97 - 4.56a
3.01 - 11.83a
0.28 - 1.19
0.56 - 2.57d
3.93 - 16.23ad
0.19 - 0.70
1.76 - 10.60a
1.99 - 10.87a

NW/OW: normal and overweight, CI: confidence interval, HTN: hypertension, Pre-DM: Pre-diabetes, DM:
Diabetes, TC: Total cholesterol, HDL: high-density lipoprotein, Non-HDL: non-high-density lipoprotein;
ApoB: apolipoprotein B, BMI: body mass index, WC: waist circumference, WHtR: waist-to-height ratio,
SAD: sagittal abdominal diameter, SADHtR: sagittal abdominal diameter-to-height ratio.
Odds ratios represent Quartile 4 compared to Quartile 1.
a
Denotes significant difference from BMI (≤0.0001 P < 0.01), b Denotes significant difference between
WC and WHtR, c Denotes significant difference between SAD and SADHtR, d Denotes significant
difference between WC and SAD, e Denotes significant difference between WHtR and SADHtR.

DISCUSSION
In the current study, it is apparent that abdominal measures that include height are
able to better predict many cardiometabolic risks among both males and females. Among
normal weight and overweight males, WHtR and SADHtR were the strongest predictors
of all cardiometabolic risks except low HDL-C. With normal weight and overweight
females, WHtR and SADHtR appear to be the best measures of risk for HTN and
diabetes, while the remaining cardiometabolic risks are predicted quite similarly between
abdominal obesity measures, except for low HDL-C. While WHtR and SADHtR may not
be significantly different from each other in disease risk assessment, both are consistently
better than abdominal obesity measures that do not include a factor of height and
especially superior to BMI. Factoring height into various abdominal measurements may
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help better predict risk of cardiometabolic diseases. Height can help to distinguish
between individuals with larger midsections related to their small or large stature versus
individuals with a high level of visceral adiposity. Many studies have supported this
theory, justifying that WHtR is a better measure than waist circumference alone.9,23–26
Overall, very few studies have been published using the general population versus
specific populations, such as severely obese individuals, gender, ethnicity, or age specific
studies. This proves difficult in comparing the current findings to such studies. However,
one study12 by Kahn and Bullard found SADHtR and WHtR tended to have higher ORs
than BMI for several cardiometabolic risks, but when compared against each other, found
that SADHtR identified better with HTN, hyper-alanine transaminase and hypergammaglutamyltransferase than did WHtR. While there are similarities to the study by
Kahn and Bullard, the current study included measures of diabetes, high total cholesterol,
low HDL-C and high ApoB as cardiometabolic risk factors. ORs for WHtR and SADHtR
were the highest among males and females for most cardiometabolic risks congruent with
findings by Kahn et al., except that study found SADHtR to be the strongest measure in
most cases. Kahn’s study also did not include WC or SAD in their comparisons, leaving
out an important aspect of this research as SAD tended to have higher ORs for several
cardiometabolic risks compared to the other abdominal obesity measures. Also, the
inclusion of WC and SAD allowed for the comparisons that included height helping to
identify whether the inclusion of height contributed to stronger risk assessment.
Gletsu-Miller et al. published a study7 involving 60 clinically severely obese
women in efforts to predict visceral adiposity in association with dysglycemia. When
comparing to BMI and WC, they found SAD to be a better estimate of visceral adiposity
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and most associated with dysglycemia related to decreased beta-cell function. The current
study demonstrated similar findings, as SAD was a stronger predictor of pre-diabetes
than WC among all adult females. With these results showing the fourth quartile
compared to the first quartile, this also coincides with that study, as the fourth quartile
among all adult females likely consists of mostly obese females. However, in the current
study, WHtR and SADHtR, while not significantly different from one another, were
stronger predictors than WC and SAD. While notable, this finding expands on GletsuMiller et al.’s findings, as measures of height were not used in that study.
Smith et al. published a study6 observing a cohort of 466 male participants in
regards to various anthropometric measures of obesity and their relation to known
coronary heart disease risk factors. When comparing BMI, WC, WHR, waist-thigh ratio,
SAD, and abdominal diameter index, Smith et al. found that abdominal diameter index
was the strongest at predicting risk of coronary heart disease after adjusting for 10-year
Framingham CHD risk. Abdominal diameter index is a ratio of SAD and thigh
circumference, emphasizing the increased importance of the use of SAD. One important
difference in that study was the absence of height in the anthropometric measurements.
Overall, the ORs for each of the anthropometric measures were very comparable and
quite possibly not significantly different than one another, as tests of significance
between each anthropometric measure were not conducted. With the absence of height,
obesity measures tended to be very similar predictors of coronary heart disease among
men, accentuating the need for an enhanced measure of obesity for disease risk
prediction. With the current study’s findings, it is clear that including measures of height
increase the ability to predict cardiometabolic risk, including heart disease risk factors.
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While the current study has many strengths, including a large nationally
representative sample consisting of four years of data, the use of ratios of abdominal
obesity to height in predicting metabolic risks, gender stratification, and a focus on the
normal weight and overweight adult population, it also has some limitations. One
limitation of this study was the use of only non-fasted laboratory measurements. While
there are many fasted laboratory measures that could assist with defining each
cardiometabolic risk and also allow for the use other cardiometabolic risks, only a third
of the participants at the MEC could be utilized, as only the morning group of
participants was required to be fasted. This significantly lowered the sample size, making
it more difficult to stratify based on normal weight or overweight status and gender. As
NHANES continues to measure SAD, future studies may be able to use more sample
years that could allow for the use of fasted laboratory measures. However, the laboratory
measures used in this research are adequate in defining cardiometabolic diseases.
Additionally, several measures of abdominal obesity were not included in this
research. Abdominal index, which is defined as waist circumference to thigh
circumference to height ratio, was not included among the anthropometric measures as
thigh circumference is not included in the NHANES physiological measurements. Hip
circumference is also not included among NHANES measurements, eliminating the
possible use of waist-hip-height ratio, a fairly new measurement. Several studies6,27,28
have included abdominal index and waist-hip-height ratio, making them intriguing
measures for future research.
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CONCLUSIONS
Abdominal measures of obesity were better predictors of risk for all
cardiometabolic disorders except low HDL-C in the normal weight and overweight
populations. Factoring height into the abdominal obesity measurements improved the
assessment of cardiometabolic disease risk. WHtR and SADHtR tended to be the best
measures for risk assessment among men and women. While some of the abdominal
measures of obesity were not significantly different than one another for some
cardiometabolic risks, all were better predictors of disease risk than BMI. Abdominal
measures of obesity, particularly those that include height, should be considered for use
in clinical practice to strengthen the ability to predict risk of cardiometabolic diseases
among normal weight and overweight populations.
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